(MCK) McKesson - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US58155Q1031
MCK: Drugs, Pharmaceuticals, Medical, Supplies, Equipment, Technology
McKesson Corporation (NYSE:MCK) stands as a pivotal player in the healthcare sector, operating across multiple segments that collectively address the diverse needs of the healthcare ecosystem. Its U.S. Pharmaceutical segment distributes a broad array of pharmaceutical products, including generics, biosimilars, and over-the-counter drugs, which are crucial for cost reduction in healthcare. This segment also offers tailored solutions to oncology and specialty practices, enhancing operational efficiency and patient care outcomes.
The Prescription Technology Solutions (RxTS) segment exemplifies McKessons foray into digital health, a rapidly growing sector. By connecting patients, providers, and biopharma companies, RxTS leverages technology to improve medication adherence and streamline supply chains, positioning the company strategically in the digital transformation of healthcare.
The Medical-Surgical Solutions segment underscores the importance of logistics in healthcare, providing essential medical supplies to various healthcare settings. This segments focus on efficient distribution supports the operational stability of healthcare facilities, contributing significantly to McKessons diversified revenue streams.
Internationally, McKesson extends its reach into global markets, navigating the complexities of varied regulatory landscapes while addressing the growing demand for healthcare products. This segment highlights the companys ability to adapt and thrive in diverse environments, offering a balanced growth opportunity.
Financially, McKesson presents a compelling case for investors. A high P/E ratio suggests market confidence in its growth potential, while a lower P/S ratio may indicate undervaluation relative to its revenue, offering a strategic entry point for investors. The companys historical performance and scalable business model further enhance its appeal.
With a rich history dating back to 1833, McKessons reputation as a reliable intermediary in the healthcare supply chain is well-established. Its ability to maintain margins while scaling operations positions it favorably in the industry, making it a noteworthy consideration for investors seeking exposure to healthcare infrastructure and digital innovation.
Additional Sources for MCK Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
MCK Stock Overview
Market Cap in USD | 80,671m |
Sector | Healthcare |
Industry | Medical Distribution |
GiC Sub-Industry | Health Care Distributors |
IPO / Inception | 1994-11-15 |
MCK Stock Ratings
Growth 5y | 89.4% |
Fundamental | 47.4% |
Dividend | 58.7% |
Rel. Strength Industry | 22.4 |
Analysts | 4.35/5 |
Fair Price Momentum | 797.08 USD |
Fair Price DCF | 373.81 USD |
MCK Dividends
Dividend Yield 12m | 0.33% |
Yield on Cost 5y | 1.74% |
Annual Growth 5y | 9.89% |
Payout Consistency | 94.5% |
MCK Growth Ratios
Growth Correlation 3m | 93.2% |
Growth Correlation 12m | 46.8% |
Growth Correlation 5y | 98.9% |
CAGR 5y | 40.81% |
CAGR/Max DD 5y | 1.71 |
Sharpe Ratio 12m | 1.17 |
Alpha | 14.25 |
Beta | 0.77 |
Volatility | 22.71% |
Current Volume | 767.3k |
Average Volume 20d | 824.7k |
As of March 15, 2025, the stock is trading at USD 650.43 with a total of 767,267 shares traded.
Over the past week, the price has changed by +0.96%, over one month by +9.68%, over three months by +14.22% and over the past year by +23.44%.
Partly, yes. Based on ValueRay Fundamental Analyses, McKesson (NYSE:MCK) is currently (March 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 47.43 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MCK as of March 2025 is 797.08. This means that MCK is currently undervalued and has a potential upside of +22.55% (Margin of Safety).
McKesson has received a consensus analysts rating of 4.35. Therefor, it is recommend to buy MCK.
- Strong Buy: 10
- Buy: 3
- Hold: 4
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, MCK McKesson will be worth about 876.8 in March 2026. The stock is currently trading at 650.43. This means that the stock has a potential upside of +34.8%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 666.7 | 2.5% |
Analysts Target Price | 650.5 | 0% |
ValueRay Target Price | 876.8 | 34.8% |